Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
- de Bono, Johann S.
- Smith, Matthew R.
- Saad, Fred
- Rathkopf, Dana E.
- Mulders, Peter F.A.
- Small, Eric J.
- Shore, Neal D.
- Fizazi, Karim
- De Porre, Peter
- Kheoh, Thian
- Li, Jinhui
- Todd, Mary B.
- Ryan, Charles J.
- Flaig, Thomas W.
DOIAbstract
Background: Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) have changed substantially in the last few years. In trial COU-AA-302 (chemotherapy-naïve men with mCRPC), abiraterone acetate plus prednisone (AA) significantly improved radiographic progression-free survival and overall survival (OS) when compared to placebo plus prednisone (P). Objective: This post hoc analysis investigated clinical responses to docetaxel as first subsequent therapy (FST) among patients who progressed following protocol-specified treatment with AA, and characterized subsequent treatment patterns among older (≥75 yr) and younger (<75 yr) patient subgroups. Design, setting, and participants Data were collected at the final OS analysi...
Add to ORKG